BioCentury
ARTICLE | Clinical News

TB Alliance begins Phase I trial of TBA-354

February 20, 2015 2:18 AM UTC

The not-for-profit Global Alliance for TB Drug Development began a U.S. Phase I trial of tuberculosis (TB) treatment TBA-354. TB Alliance said the next generation nitroimidazole is the first new TB candidate to enter clinical testing since 2009.

TB Alliance said the compound's anti-bactericidal and sterilizing activity in preclinical studies were stronger than that of its pretomanid ( PA-824), a nitroimidazopyran included in combination regimens undergoing Phase II and Phase III trials to treat multidrug-resistant TB (MDR-TB). It also said oral TBA-354 had more favorable pharmacokinetic properties than Deltyba delamanid from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan), a nitro-dihydro-imidazooxazole derivative approved in Japan to treat MDR-TB and conditionally approved in the EU to treat pulmonary MDR-TB in adults when alternative treatments cannot be used due to resistance or intolerance. ...